As China's Lunar Year of the Horse approaches, the 25th Nanjing (National) Spring Festival Food and Commodity Fair has ...
Summit Therapeutics has moved ahead in the race to bring a therapy targeting both VEGF and PD- (L)1 to market, after the FDA started a review of its ivonescimab drug for lung cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results